Amrad Corporation Limited

Research Corporation Technologies, Inc.

Zenyth Operations Pty. Ltd.

Nicholas Martin Gough

Donald Metcalf

Nicos Anthony Nicola

David P Gearing

Douglas James Hilton

Richard John Simpson

Tracy Ann Willson

Edouard C Nice

Julie Ann King

Robert Frederick Seamark

Julie A King

Tracey Ann Willson

Robert Lindsay Williams

Edouard Collins Nice

Meredith Jane Layton

Nicos Antony Nicola

Catherine Mary Owczarek

Ashley R Dunn

David Paul Gearing

The present invention relates to the use of leukemia inhibitory factor (LIF) in the isolation and propagation of embryonic stem cells in vitro.

In vitro propagation of embryonic stem cells

The present invention provides isolated DNA molecules encoding human and murine LIF and methods of producing LIF by the expression of the isolated DNA and suitable host cells. The invention further provides human and murine LIF polypeptides, pharmaceutical compositions containing LIF, and methods of use thereof.

Leukaemia inhibitory factor

The present invention relates generally to molecules carrying one or more binding determinants for &agr;-chain of human Leukaemia Inhibitory Factor binding receptor and to genetic sequences encoding same. More particularly, the present invention contemplates a molecule which is non-naturally occurring and which comprises a carrier portion and an active portion and wherein the active portion comprises amino acid residues or chemical equivalents thereof which constitute a binding determinant for the &agr; chain of the human leukaemia inhibitory factor (hLIF) binding receptor.

Receptor-binding determinant from leukaemia inhibitory factor

The invention provides a recombinant or synthetic receptor or a derivative thereof, for granulocyte-macrophage colony-stimulating factor (GM-CSF). The GM-CSF receptor is useful, inter alia, in the treatment or diagnosis of GM-CSF-related diseases, and in the screening of agonists and antagonists of GM-CSF receptors. The invention further provides antibodies directed against GM-CSF receptor or derivatives thereof, and pharmaceutical compositions comprising either the GM-CSF receptor, the receptor derivative, or an antibody thereto, and methods of using thereof.

Antibodies which bind granulocyte-macrophane colony-stimulating factor

Leukemia inhibitory factor or LIF as an addition to culture media promotes the development of embryos to the implantation stage. Growth in the presence of LIF increases the percentage of embryos that reach the implantation stage than growth without LIF. LIF is isolatable from several mammalian species such as murine, sheep, pig, cow, horse or donkey.

Leukemia inhibitory factor from mammalian species and use thereof to

The present invention provides isolated DNA molecules encoding human and murine LIF, and methods of producing LIF by the expression of the isolated DNA in suitable host cells. The invention further provides human and murine LIF polypeptides, pharmaceutical compositions containing LIF, and methods of use thereof.

The invention provides a recombinant or synthetic receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF) and biochemical and/or biological equivalents, homologues, or derivatives thereof. The GM-CSF receptor is useful inter alia in treatment and diagnosis of GM-CSF related diseases, and in screening of agonists and antagonists of binding of GM-CSF to its cell-bound receptors. The invention further provides nucleic acid sequences encoding GM-CSF receptor, recombinant DNA molecules comprising these sequences, and transformed hosts carrying the recombinant DNA molecules, as well as antibodies directed against GM-CSF receptor, and pharmaceutical compositions comprising either the GM-CSF receptor or antibody thereto.

Granulocyte-macrophage colony-stimulating factor receptor and

Disclosed is the in vitro development of mammalian embryos to the implantation stage by culturing the embryos in a medium containing leukemia inhibitory factor (LIF).

Leukaemia inhibitory factor from livestock species and use thereof to

The invention provides a recombinant or synthetic receptor for granulocyte-macrophage colony-stimulating factor (GM-CSF) and biochemical and/or biological equivalents, homologues, or derivatives thereof. The GM-CSF receptor is useful inter alia in treatment and diagnosis of GM-CSF related diseases, and in screening of agonists and antagonists of binding of GM-CSF to its cell-bound receptors. The invention further provides nucleic acid sequences encoding GM-CSF receptor, recombinant DNA molecules comprising these sequences, and transformed hosts carrying the recombinant DNA molecules, as well as antibodies directed against GM-CSF receptor, and pharmaceutical compositions comprising either the GM-CSF receptor or antibodies thereto.

This invention provides a DNA sequence coding for a mammalian granulocyte macrophage colony stimulating factor (GM-CSF), a method of obtaining same, vectors and hosts harboring same. The sequence is useful as a probe for identifying related sequences, selecting GM-CSF encoding mRNA from a mixture of mRNAs containing same, and a source of GM-CSF DNA for expression in an appropriate expression vector. The GM-CSF protein encoded by the sequence is useful for stimulating the production of granulocytes and macrophages from their respective progenitor cells.

Recombinant DNA molecules

Leukemia-inhibitory factor (LIF) has been produced in essentially pure form from murine or human sources. A method of purifying this LIF is disclosed, as well as polypeptides having LIF activity which are not identical in amino acid sequence to any naturally occurring form of LIF. The polypeptides can be used for hindering the proliferation of myeloid Leukemia cells.

Human leukemia inhibitory factor

The present invention provides a method for producing recombinant leukemia inhibitory factor (LIF) by the expression, in suitable host cells, of recombinant DNA molecules encoding LIF.

Recombniant method for making leukemia inhibitor factor

A leukaemia-inhibitory factor (LIF) is disclosed, together with a method of preparation of LIF in essentially pure form. Nucleotide and amino acid sequences are disclosed, together with recombinant DNA moleclues and host cells for production of polypeptides having LIF activity.

Growing community of inventors

North Balwyn, Australia

Nicholas Martin Gough